Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desloratadine
Drug ID BADD_D00615
Description Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
Indications and Usage For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
Marketing Status approved; investigational
ATC Code R06AX27
DrugBank ID DB00967
KEGG ID D03693
MeSH ID C121345
PubChem ID 124087
TTD Drug ID D01GBY
NDC Product Code 53104-7613; 55111-360; 52408-0130; 66577-018; 68180-153; 62993-0805; 75895-0099; 78206-188; 65015-698; 69543-107; 71335-1000; 65691-0057; 66039-830; 50090-3975; 78206-119; 53104-7688; 62331-019; 50090-4794; 62250-619; 42291-240; 55111-551; 55111-073
UNII FVF865388R
Synonyms desloratadine | descarboethoxyloratadine | SCH 34117 | SCH-34117 | Clarinex | Neoclarityn | Aerius | descarboethoxyloratadine acetate
Chemical Information
Molecular Formula C19H19ClN2
CAS Registry Number 100643-71-8
SMILES C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumomediastinum22.09.03.0040.001018%Not Available
Eye pruritus06.04.05.0060.002307%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.005--
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.0070.001018%Not Available
Mental disorder19.07.01.002--Not Available
Amnestic disorder19.20.05.001; 17.03.02.0070.001357%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Adverse drug reaction08.06.01.009--Not Available
Autonomic neuropathy17.05.01.009--Not Available
Psychotic disorder19.03.01.0020.001018%
Hepatobiliary disease09.01.08.003--Not Available
Unevaluable event08.01.03.051--Not Available
Oesophageal oedema07.11.02.0020.000678%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000678%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.003053%Not Available
Concomitant disease aggravated08.01.03.063--Not Available
Oesophageal dilatation07.11.02.0050.000678%Not Available
Sopor19.02.04.002; 17.02.04.0210.000678%Not Available
Behaviour disorder19.01.01.0050.001357%Not Available
Cold urticaria23.04.02.014; 10.01.06.014--Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.001493%Not Available
Illness08.01.03.091--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages